Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung Young | - |
dc.contributor.author | Jung, Sung Woo | - |
dc.contributor.author | Kim, Jeong Han | - |
dc.contributor.author | Koo, Ja Seol | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Park, Jong Jae | - |
dc.contributor.author | Chun, Hoon Jai | - |
dc.contributor.author | Lee, Sang Woo | - |
dc.contributor.author | Choi, Jai Hyun | - |
dc.date.accessioned | 2021-09-06T23:21:08Z | - |
dc.date.available | 2021-09-06T23:21:08Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-01 | - |
dc.identifier.issn | 0306-5251 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/109147 | - |
dc.description.abstract | AIM We compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H. pylori infection. METHODS Two hundred and four H. pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment. RESULTS The eradication rate was 82.8% in the triple therapy group and 78.4% in the dual therapy group by per protocol analysis. This difference was not significant (P = 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P = 0.002). CONCLUSIONS Because dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H. pylori eradication in Korea. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.subject | PROTON PUMP INHIBITOR | - |
dc.subject | TRIPLE THERAPY | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | GENOTYPIC DIFFERENCES | - |
dc.subject | PLUS AMOXICILLIN | - |
dc.subject | CURE RATES | - |
dc.subject | CLARITHROMYCIN | - |
dc.subject | ERADICATION | - |
dc.subject | ULCER | - |
dc.subject | METRONIDAZOLE | - |
dc.title | Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Seung Young | - |
dc.contributor.affiliatedAuthor | Jung, Sung Woo | - |
dc.contributor.affiliatedAuthor | Koo, Ja Seol | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Park, Jong Jae | - |
dc.contributor.affiliatedAuthor | Chun, Hoon Jai | - |
dc.contributor.affiliatedAuthor | Lee, Sang Woo | - |
dc.contributor.affiliatedAuthor | Choi, Jai Hyun | - |
dc.identifier.doi | 10.1111/j.1365-2125.2011.04048.x | - |
dc.identifier.scopusid | 2-s2.0-83155173136 | - |
dc.identifier.wosid | 000297790200017 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, v.73, no.1, pp.140 - 143 | - |
dc.relation.isPartOf | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | - |
dc.citation.title | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | - |
dc.citation.volume | 73 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 140 | - |
dc.citation.endPage | 143 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | PROTON PUMP INHIBITOR | - |
dc.subject.keywordPlus | TRIPLE THERAPY | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | GENOTYPIC DIFFERENCES | - |
dc.subject.keywordPlus | PLUS AMOXICILLIN | - |
dc.subject.keywordPlus | CURE RATES | - |
dc.subject.keywordPlus | CLARITHROMYCIN | - |
dc.subject.keywordPlus | ERADICATION | - |
dc.subject.keywordPlus | ULCER | - |
dc.subject.keywordPlus | METRONIDAZOLE | - |
dc.subject.keywordAuthor | amoxicillin | - |
dc.subject.keywordAuthor | administration and dosage | - |
dc.subject.keywordAuthor | combination | - |
dc.subject.keywordAuthor | drug therapy | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.subject.keywordAuthor | drug therapy | - |
dc.subject.keywordAuthor | proton pump inhibitors | - |
dc.subject.keywordAuthor | administration and dosage | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.